Free Trial

CRISM Therapeutics (CRTX) Competitors

GBX 23 -1.80 (-7.26%)
As of 12:31 PM Eastern

CRTX vs. GLR, PXC, BRES, TGR, CLA, VAST, BMN, SML, PREM, and FRG

Should you be buying CRISM Therapeutics stock or one of its competitors? The main competitors of CRISM Therapeutics include Galileo Resources (GLR), Phoenix Copper (PXC), Blencowe Resources (BRES), Tirupati Graphite (TGR), Celsius Resources (CLA), Vast Resources (VAST), Bushveld Minerals (BMN), Strategic Minerals (SML), Premier African Minerals (PREM), and Firering Strategic Minerals (FRG). These companies are all part of the "other industrial metals & mining" industry.

CRISM Therapeutics vs. Its Competitors

CRISM Therapeutics (LON:CRTX) and Galileo Resources (LON:GLR) are both small-cap basic materials companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

In the previous week, CRISM Therapeutics had 1 more articles in the media than Galileo Resources. MarketBeat recorded 1 mentions for CRISM Therapeutics and 0 mentions for Galileo Resources. CRISM Therapeutics' average media sentiment score of 1.38 beat Galileo Resources' score of 0.00 indicating that CRISM Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
CRISM Therapeutics Positive
Galileo Resources Neutral

8.9% of Galileo Resources shares are held by institutional investors. 68.8% of CRISM Therapeutics shares are held by company insiders. Comparatively, 74.8% of Galileo Resources shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Galileo Resources is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM TherapeuticsN/AN/A-£792.20K-£5.81-3.96
Galileo ResourcesN/AN/A-£1.05M-£0.09-9.57

CRISM Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Galileo Resources has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Galileo Resources received 85 more outperform votes than CRISM Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
CRISM TherapeuticsN/AN/A
Galileo ResourcesOutperform Votes
85
59.86%
Underperform Votes
57
40.14%

Galileo Resources' return on equity of -9.30% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -13.12% -26.77%
Galileo Resources N/A -9.30%-4.51%

Summary

Galileo Resources beats CRISM Therapeutics on 7 of the 11 factors compared between the two stocks.

Get CRISM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRTX vs. The Competition

MetricCRISM TherapeuticsOther Industrial Metals & Mining IndustryMaterials SectorLON Exchange
Market Cap£2.51M£1.03B£3.20B£2.92B
Dividend YieldN/A6.20%5.03%4.90%
P/E Ratio-3.9654.7464.60119.50
Price / SalesN/A20,604.9326,914,679,906,558,600.00242,015.15
Price / CashN/A24.7024.2628.07
Price / Book0.536.735.394.73
Net Income-£792.20K£71.37M£155.18M£5.91B
7 Day Performance21.05%0.44%1.13%6.51%
1 Month Performance27.78%9.37%8.99%13.46%
1 Year PerformanceN/A31.09%23.21%28.79%

CRISM Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRTX
CRISM Therapeutics
N/AGBX 23
-7.3%
N/AN/A£2.51MN/A-3.964Positive News
Earnings Report
High Trading Volume
GLR
Galileo Resources
N/AGBX 0.92
-0.5%
N/A-12.4%£10.70MN/A-10.171
PXC
Phoenix Copper
N/AGBX 4.66
-11.3%
N/A-80.4%£10.02MN/A-4.0818Gap Down
High Trading Volume
BRES
Blencowe Resources
N/AGBX 3.36
+8.5%
N/A-37.2%£9.96MN/A-7.783Gap Up
High Trading Volume
TGR
Tirupati Graphite
N/AN/AN/AN/A£8.67M£4.38M-2.4136,000
CLA
Celsius Resources
N/AGBX 0.33
flat
N/A-43.5%£8.35M£647.000.00N/AGap Up
VAST
Vast Resources
N/AGBX 0.44
-1.8%
N/A+134.2%£8M£3.58M-44.20350News Coverage
Gap Down
BMN
Bushveld Minerals
N/AN/AN/AN/A£7.07M£107.92M-5.10758
SML
Strategic Minerals
N/AGBX 0.28
-3.4%
N/A+51.4%£7.06M£4.65M-0.6511Gap Down
PREM
Premier African Minerals
N/AGBX 0.01
flat
N/A-88.1%£6.18MN/A-0.1919High Trading Volume
FRG
Firering Strategic Minerals
N/AGBX 2.78
-0.9%
N/A-15.9%£6.12MN/A-2.37N/AHigh Trading Volume

Related Companies and Tools


This page (LON:CRTX) was last updated on 6/16/2025 by MarketBeat.com Staff
From Our Partners